EARS - Auris Medical announces initiation of clinical investigation of AM-301 in allergic rhinitis

Auris Medical (EARS) with its affiliate Altamira Medica AG announces the initiation of a clinical investigation of AM-301, a drug-free nasal spray, in allergic rhinitis.The clinical investigation is an open-label randomized cross-over study enrolling 36 patients with allergic rhinitis to grass pollen.Study participants will be administered a single dose of AM-301 nasal spray or a comparator product (one puff into each nostril) prior to controlled pollen exposure for four hours in an allergen challenge chamber.The main goal of the study will be based on the difference in the Total Nasal Symptom Score between the two treatments over the 4-hours.The company aims to launch AM-301 in selected markets in late Q2 2021.Beside the development of AM-301 for use in allergy management, Altamira Medica is advancing the testing of the nasal spray for use in the protection against infections from airborne viruses such as SARS-CoV-2, Auris said.Auris shares up ~7% premarket.

For further details see:

Auris Medical announces initiation of clinical investigation of AM-301 in allergic rhinitis